[
    [
        {
            "time": "2018-05-15",
            "original_text": "Incyte Begins Phase III Study for Treatment of Duct Cancer",
            "features": {
                "keywords": [
                    "Incyte",
                    "Phase III",
                    "Treatment",
                    "Duct Cancer"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "Incyte Begins Phase III Study for Treatment of Duct Cancer",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-09-21",
            "original_text": "Lilly's Emgality Gets FDA Approval for Cluster Headache",
            "features": {
                "keywords": [
                    "Lilly",
                    "Emgality",
                    "FDA Approval",
                    "Cluster Headache"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "Lilly's Emgality Gets FDA Approval for Cluster Headache",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-13",
            "original_text": "Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology",
            "features": {
                "keywords": [
                    "Lilly",
                    "New Data",
                    "Patient-Centered",
                    "Solutions",
                    "European Congress",
                    "Rheumatology"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly to Present New Data and Commitment to Patient-Centered Solutions at the Annual European Congress of Rheumatology",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        }
    ]
]